Dore GJ - Search Results

1

Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection.

Martinello M, Bhagani S, Gane E, Orkin C, Cooke G, Dore GJ, Petoumenos K, Applegate TL, Tu E, Marks P, Pagani N, Grebely J, Nelson M, Matthews GV. Martinello M, et al. Among authors: dore gj. J Viral Hepat. 2018 Oct;25(10):1180-1188. doi: 10.1111/jvh.12917. Epub 2018 May 8. J Viral Hepat. 2018. PMID: 29660224 Clinical Trial.

2

Predicting progression to cirrhosis in chronic hepatitis C virus infection.

Freeman AJ, Law MG, Kaldor JM, Dore GJ. Freeman AJ, et al. Among authors: dore gj. J Viral Hepat. 2003 Jul;10(4):285-93. doi: 10.1046/j.1365-2893.2003.00436.x. J Viral Hepat. 2003. PMID: 12823595 Review.

3

HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy.

Lincoln D, Petoumenos K, Dore GJ; Australian HIV Observational Database. Lincoln D, et al. Among authors: dore gj. HIV Med. 2003 Jul;4(3):241-9. doi: 10.1046/j.1468-1293.2003.00152.x. HIV Med. 2003. PMID: 12859323 Free article.

4

Treatment for hepatitis C virus infection among current injection drug users in Australia.

Matthews G, Kronborg IJ, Dore GJ. Matthews G, et al. Among authors: dore gj. Clin Infect Dis. 2005 Apr 15;40 Suppl 5:S325-9. doi: 10.1086/427448. Clin Infect Dis. 2005. PMID: 15768342 Review.

5

Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies.

Micallef JM, Kaldor JM, Dore GJ. Micallef JM, et al. Among authors: dore gj. J Viral Hepat. 2006 Jan;13(1):34-41. doi: 10.1111/j.1365-2893.2005.00651.x. J Viral Hepat. 2006. PMID: 16364080 Review.

6

Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.

Matthews GV, Bartholomeusz A, Locarnini S, Ayres A, Sasaduesz J, Seaberg E, Cooper DA, Lewin S, Dore GJ, Thio CL. Matthews GV, et al. Among authors: dore gj. AIDS. 2006 Apr 4;20(6):863-70. doi: 10.1097/01.aids.0000218550.85081.59. AIDS. 2006. PMID: 16549970

7

Response to Schmutz et al., 'Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection'.

Matthews GV, Dore GJ. Matthews GV, et al. Among authors: dore gj. AIDS. 2007 Mar 30;21(6):777-8. doi: 10.1097/QAD.0b013e3280b07774. AIDS. 2007. PMID: 17413705 No abstract available.

8

High incidence of hepatitis C virus reinfection within a cohort of injecting drug users.

Micallef JM, Macdonald V, Jauncey M, Amin J, Rawlinson W, van Beek I, Kaldor JM, White PA, Dore GJ. Micallef JM, et al. Among authors: dore gj. J Viral Hepat. 2007 Jun;14(6):413-8. doi: 10.1111/j.1365-2893.2006.00812.x. J Viral Hepat. 2007. PMID: 17501762

9

Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir.

Matthews GV, Cooper DA, Dore GJ. Matthews GV, et al. Among authors: dore gj. Antivir Ther. 2007;12(1):119-22. Antivir Ther. 2007. PMID: 17503756

10

Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection.

Dore GJ, Torriani FJ, Rodriguez-Torres M, Bräu N, Sulkowski M, Lamoglia RS, Tural C, Clumeck N, Nelson MR, Mendes-Correa MC, Godofsky EW, Dieterich DT, Yetzer E, Lissen E, Cooper DA. Dore GJ, et al. AIDS. 2007 Jul 31;21(12):1555-9. doi: 10.1097/QAD.0b013e328216f2c7. AIDS. 2007. PMID: 17630550 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

525 results

Search Page

Filters